Deng Chunmin, Zhang Hao, Song Li
Suzhou Research Center of Medical School, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University, Suzhou, 215153, Jiangsu Province, China.
YanCheng No. 1 People's Hospital, Yancheng, 224001, China.
Discov Oncol. 2024 Aug 5;15(1):334. doi: 10.1007/s12672-024-01214-7.
Nanoparticle-based photothermal therapy (PTT) has emerged as a promising approach in tumor treatment due to its high selectivity and low invasiveness. However, the penetration of near-infrared light (NIR) is limited, leading it fails to induce damage to the deep-seated tumor cells within the tumor tissue. Additionally, inefficient uptake of photothermal nanoparticles by tumor cells results in suboptimal outcomes for PTT. In this study, we utilized the adhesive properties of photothermal material, polydopamine (PDA), which can successfully load the photosensitizer indocyanine green (ICG) and chemotherapeutic drug doxorubicin (DOX) to achieve photothermal and chemotherapy synergy treatment (PDA/DOX&ICG), aiming to compensate the defects of single tumor treatment. To extending the blood circulation time of PDA/DOX&ICG nanoparticles, evading clearance by the body immune system and achieving targeted delivery to tumor tissues, a protective envelopment was created using erythrocyte membranes modified with folate acid (FA-EM). After reaching the tumor tissue, the obtained FA-EM@PDA/DOX&ICG nanoparticles can specific bind with folate acid receptors on the surface of tumor cells, which can improve the uptake behavior of FA-EM@PDA/DOX&ICG nanoparticles by tumor cells, and leading to the release of loaded DOX and ICG in response to the unique tumor microenvironment. ICG, as a typical photosensitizer, significantly enhances the photothermal conversion performance of FA-EM@PDA/DOX&ICG nanoparticles, thus inducing tumor cells damage. In vitro and in vivo experimental results demonstrated that the coordinated NIR treatment with FA-EM@PDA/DOX&ICG not only effectively inhibits tumor growth, but also exhibits superior biocompatibility, effectively mitigating DOX-induced tissue damage.
基于纳米颗粒的光热疗法(PTT)因其高选择性和低侵入性,已成为肿瘤治疗中一种很有前景的方法。然而,近红外光(NIR)的穿透能力有限,导致其无法对肿瘤组织内的深层肿瘤细胞造成损伤。此外,肿瘤细胞对光热纳米颗粒的摄取效率低下,导致光热疗法的效果不理想。在本研究中,我们利用光热材料聚多巴胺(PDA)的粘附特性,其能够成功负载光敏剂吲哚菁绿(ICG)和化疗药物阿霉素(DOX),以实现光热与化疗协同治疗(PDA/DOX&ICG),旨在弥补单一肿瘤治疗的缺陷。为了延长PDA/DOX&ICG纳米颗粒的血液循环时间,逃避机体免疫系统的清除并实现对肿瘤组织的靶向递送,我们使用叶酸(FA)修饰的红细胞膜构建了一种保护性包膜(FA-EM)。到达肿瘤组织后,所制备的FA-EM@PDA/DOX&ICG纳米颗粒能够与肿瘤细胞表面的叶酸受体特异性结合,这可以改善肿瘤细胞对FA-EM@PDA/DOX&ICG纳米颗粒的摄取行为,并导致负载的DOX和ICG响应独特的肿瘤微环境而释放。ICG作为一种典型的光敏剂,显著增强了FA-EM@PDA/DOX&ICG纳米颗粒的光热转换性能,从而诱导肿瘤细胞损伤。体外和体内实验结果表明,FA-EM@PDA/DOX&ICG的近红外协同治疗不仅能有效抑制肿瘤生长,还具有优异的生物相容性,有效减轻了DOX诱导的组织损伤。